genentech
-
Of Course 23andMe’s Plan Has Been To Sell Your Genetic Data All Along
Today, 23andMe announced what Forbes reports is only the first of 10 deals with big biotech companies: Genentech will pay up to $US60 million for access to 23andMe’s data to study Parkinson’s. You think 23andMe was about selling fun DNA spit tests for $US99 a pop? Nope, it’s been about selling your data all along.